Rate of response to initial antiretroviral therapy according to level of pre‐existing HIV‐1 drug resistance detected by next‐generation sequencing in the strategic timing of antiretroviral treatment (START) study

The main objective of this analysis was to evaluate the impact of pre‐existing drug resistance by next‐generation sequencing (NGS) on the risk of treatment failure (TF) of first‐line regimens in participants enrolled in the START study.

[1]  K. Ruxrungtham,et al.  Phylogenetic analysis of HIV-1 shows frequent cross-country transmission and local population expansions , 2021, Virus evolution.

[2]  M. Kozal,et al.  Transmitted HIV‐1 drug resistance in a large international cohort using next‐generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study , 2020, HIV medicine.

[3]  T. F. Rinke de Wit,et al.  Low-abundance drug-resistant HIV-1 variants in antiretroviral drug-naïve individuals: A systematic review of detection methods, prevalence, and clinical impact. , 2019, The Journal of infectious diseases.

[4]  R. Xin,et al.  Detection of pretreatment minority HIV-1 reverse transcriptase inhibitor-resistant variants by ultra-deep sequencing has a limited impact on virological outcomes , 2019, The Journal of antimicrobial chemotherapy.

[5]  T. F. Rinke de Wit,et al.  Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. , 2018, The lancet. HIV.

[6]  V. Calvez,et al.  Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  R. Paredes,et al.  The Role of HIV‐1 Drug‐Resistant Minority Variants in Treatment Failure , 2017, The Journal of infectious diseases.

[8]  J. Aerssens,et al.  Deep sequencing analysis of HIV‐1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE , 2016, Journal of medical virology.

[9]  R. Paredes,et al.  Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing , 2016, AIDS.

[10]  E. Arts,et al.  Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure , 2016, Antimicrobial Agents and Chemotherapy.

[11]  C. Nielsen,et al.  Identification of minority resistance mutations in the HIV-1 integrase coding region using next generation sequencing. , 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  W. Heneine,et al.  Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy , 2015, PloS one.

[13]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[14]  R. Paredes,et al.  Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease , 2015, AIDS.

[15]  C. Charpentier,et al.  Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response. , 2015, The Journal of antimicrobial chemotherapy.

[16]  A. Geretti,et al.  Global HIV‐1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial , 2015, HIV medicine.

[17]  K. Metzner,et al.  Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon . , 2015, The Journal of antimicrobial chemotherapy.

[18]  Karin J. Metzner,et al.  Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing , 2014, The Journal of antimicrobial chemotherapy.

[19]  K. Metzner,et al.  Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients , 2014, AIDS.

[20]  Richard Gibson,et al.  Contribution of Human Immunodeficiency Virus Type 1 Minority Variants to Reduced Drug Susceptibility in Patients on an Integrase Strand Transfer Inhibitor-Based Therapy , 2014, PloS one.

[21]  Ronan Boulmé,et al.  Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure , 2014, AIDS.

[22]  Alyssa J. Porter,et al.  Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy , 2014, PloS one.

[23]  David L. Robertson,et al.  Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism , 2014, Antimicrobial Agents and Chemotherapy.

[24]  Ingrid A. Beck,et al.  Simultaneous and sensitive detection of human immunodeficiency virus type 1 (HIV) drug resistant genotypes by multiplex oligonucleotide ligation assay. , 2013, Journal of virological methods.

[25]  D. Kuritzkes,et al.  Clinical implications of HIV-1 minority variants. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Robert W. Shafer,et al.  HIV-1 Antiretroviral Resistance , 2012, Drugs.

[27]  B. Masquelier,et al.  Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. , 2011, JAMA.

[28]  S. Hammer,et al.  Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. , 2010, The Journal of infectious diseases.

[29]  R. Paredes,et al.  Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. , 2010, The Journal of infectious diseases.

[30]  P. Gorry,et al.  Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  W. Heneine,et al.  Low-Frequency K103N Strengthens the Impact of Transmitted Drug Resistance on Virologic Responses to First-Line Efavirenz or Nevirapine-Based Highly Active Antiretroviral Therapy , 2009, Journal of acquired immune deficiency syndromes.

[32]  Anne-Mieke Vandamme,et al.  Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.

[33]  K. Metzner,et al.  Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.

[35]  R. Paredes,et al.  Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. , 2007, Journal of virological methods.

[36]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[37]  Jeroen Aerssens,et al.  VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering , 2015, Bioinform..

[38]  R. Shafer,et al.  HIV-1 Antiretroviral Resistance Scientific Principles and Clinical Applications , 2012 .

[39]  Tommy F. Liu,et al.  Surfing The Web: Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation , 2006 .

[40]  W P Havens,et al.  Viral hepatitis. , 1970, The Medical clinics of North America.